Preclinical Phase

RedHill Biopharma Ltd's (NASDAQ: RDHL) opaganib (ABC294640), an oral drug candidate for hospitalized COVID-19 patients, demonstrated potent in vitro efficacy against the omicron variant while maintaining host cell viability.  The Company says that based on the new and...

Shattuck Labs Inc (NASDAQ: STTK) announced preclinical data at the 2022 American Association for Cancer Research (AACR) Annual Meeting, including data from SL-9258 (TIGIT-Fc-LIGHT) and the Company's GADLEN platform. Preclinical data for SL-9258 (TIGIT-Fc-LIGHT), a bispecific...

Biomea Fusion Inc (NASDAQ: BMEA) presented new preclinical data at the American Association of Cancer Research (AACR) Annual Meeting for BMF-219 in liquid cancers and solid tumors. BMF-219 exhibited cytotoxic activity as a single agent at similar concentrations across multiple...

Cellectis SA (NASDAQ: CLLS) released preclinical data on its product candidate UCART20x22 at the American Association for Cancer Research (AACR) Annual Meeting.  The Company said that the data showed preclinical proof of concept with the potential to overcome common mechanisms...

Hoth Therapeutics Inc (NASDAQ: HOTH) shares are surging after announcing development updates for its novel cancer therapeutic, HT-KIT. Through a sponsored scientific research agreement with North Carolina State University, the team used the HT-KIT mRNA frame-shifting approach on...

Surface Oncology Inc (NASDAQ: SURF) announced the presentation of new preclinical and translational data for SRF388, a first-in-class antibody targeting IL-27, at the American Association for Cancer Research (AACR) Annual Meeting 2022. Pharmacokinetics (PK) from the dose-escalation phase of...

Syros Pharmaceuticals Inc (NASDAQ: SYRS) announced new preclinical data from its CDK12 inhibitor program, demonstrating robust anti-tumor activity in models of breast, lung, and ovarian cancer, including in a PARP inhibitor-resistant model.  The data support the advancement of...

Codiak BioSciences Inc (NASDAQ: CDAK) announced new preclinical data on its engineered exosome precision medicine candidate, exoASO-C/EBPβ.  The data demonstrate that exoASO-C/EBPβ induces potent single-agent anti-tumor activity by repolarizing myeloid cells in the...

Nurix Therapeutics Inc (NASDAQ: NRIX) announced the presentation of preclinical data of NX-2127 and DeTIL-0255 for B-cell malignancies and solid tumors, respectively, at the American Association for Cancer Research (AACR) Annual Meeting.  The data demonstrate the bifunctional...

Vincerx Pharma Inc (NASDAQ: VINC) announced a poster presentation of preclinical and preliminary clinical data on VIP152 in gynecologic cancer cell lines and patients with gynecologic malignancies, respectively. The data were shared at the 2022 American Association for Cancer...

Phio Pharmaceuticals Corp (NASDAQ: PHIO) has presented new preclinical data for PH-894, a self-delivering RNAi compound targeting the bromodomain-containing protein 4 (BRD4) The preclinical data exhibited that PH-894 inhibits tumor growth in both PD-1 inhibition responsive and PD-1...

Addex Therapeutics (NASDAQ: ADXN) has moved a selective and potent M4 muscarinic receptor positive allosteric modulator (PAM) program into lead optimization, with a potential treatment of schizophrenia and other neuropsychiatric disorders. Using its proprietary allosteric modulator...

VBI Vaccines Inc (NASDAQ: VBIV) announced updated clinical and preclinical data from its VBI-2900 coronavirus program, consisting of three candidates. VBI-2902 and VBI-2905, evaluated at a low dose of 5µg, were well-tolerated in clinical studies, with no safety signals...

Oncology and antiviral drugs focused Sunshine Biopharma Inc (NASDAQ: SBFM) has said that two of its newly designed mRNA molecules can effectively destroy cancer cells grown in culture.  What Happened: The cytotoxicity tests were performed on various cancer cells, including...

Stealth BioTherapeutics Corp (NASDAQ: MITO) announced the presentation of new SBT-272 preclinical data and dosing of the first subject in its Phase 1 trial of SBT-272. The new data demonstrated behavioral and metabolic improvements with SBT-272 in a mouse model of Huntington's...